XORTX Therapeutics (XRTX) Q1 2025 earnings summary

Executive summary

• XORTX Therapeutics is a late-stage clinical pharmaceutical company focused on therapies for gout, ADPKD, T2 diabetic nephropathy, and AKI associated with respiratory virus infection.

• The company is advancing four main programs, with XRx-026 (gout) and XRx-008 (ADPKD) as lead candidates, both targeting regulatory submissions and commercialization.

• Recent FDA feedback clarified steps for NDA submission for XRx-026, and a new European patent was granted for proprietary formulations.

• No product revenue has been generated to date; the company relies on external financing to fund operations and R&D.

Financial highlights

• Net loss for Q1 2025 was $698,673 ($0.19/share), a significant improvement from a net loss of $3,018,936 ($1.24/share) in Q1 2024, mainly due to a gain on derivative warrant liability and lower investor relations expenses.

• Cash balance at March 31, 2025 was $1,895,238, down from $2,473,649 at December 31, 2024.

• Operating cash outflow for Q1 2025 was $643,730, compared to $1,303,852 in Q1 2024.

• Research and development expenses increased to $276,309 in Q1 2025 from $73,643 in Q1 2024, reflecting increased clinical and regulatory activities.

• Financing activities in Q1 2025 raised $67,577, primarily from an at-the-market offering.

Outlook and guidance

• XORTX plans to submit an IND and NDA for XRx-026 in 2025, targeting commercialization in late 2026, with estimated costs of $9–18 million.

• The pivotal registration trial for XRx-008 (ADPKD) is planned for 2025, subject to financing, with estimated costs of $5–30 million.

• Additional programs (XRx-101, XRx-225) will advance as funding allows; focus remains on non-dilutive and dilutive funding and potential partnerships.

• Current cash burn is ~$250,000/month; management believes additional funding can be raised as needed.